News Details

View all news

Mirati Therapeutics To Provide Updated Sitravatinib Clinical Data At The European Society For Medical Oncology (ESMO) 2018 Congress And Conduct Investor Call

- Two oral presentations will feature updated clinical data from an ongoing phase 2 clinical trial of sitravatinib in combination with nivolumab and a Phase 1b clinical trial of sitravatinib as a single agent
- Proffered Paper Sessions (oral presentations) will include additional clinical trial data beyond data included in the abstracts
- Company to host investor conference call and webcast on Monday, October 22nd at 2:00 p.m. CEST/8:00 a.m. EDT/5:00 a.m. PDT

SAN DIEGO, Oct. 15, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that in conjunction with the two Proffered Papers Sessions (oral presentations) highlighting data from ongoing clinical trials of sitravatinib, the Company will conduct an investor conference call during the 2018 Annual Meeting of the European Society for Medical Oncology in Munich, Germany, on October 22nd at 2:00 p.m. CEST/8:00 a.m. EDT/5:00 a.m. PDT.

The Proffered Papers (Oral Presentations) Details:

Title: Sitravatinib demonstrates activity in patients with novel genetic alterations that inactivate CBL
Presentation Topic: Proffered paper session - Developmental therapeutics (ID 170)
Location: Hall B3 - Room 22, ICM München, Munich, Germany 
Lecture Date and Time: October 21, 2018, at 11:00 a.m. - 11:12 a.m. CEST
Presentation Number: 408O
Presenter: Lyudmila Bazhenova, M.D.

The data being presented in this oral presentation will feature data from the ongoing Phase 1b trial of sitravatinib monotherapy in patients with certain genetic alterations.

Title: Stage 2 enrollment complete: Sitravatinib in Combination with Nivolumab in NSCLC Patients Progressing on Prior Checkpoint Inhibitor Therapy
Presentation Topic: Proffered paper session - Immunotherapy of Cancer (ID 159)
Location: Hall A2 - Room 18, ICM München, Munich, Germany
Lecture Date and Time: October 22, 2018, at 12:06 p.m. - 12:18 p.m. CEST
Presentation Number: 1129O 
Presenter: Ticiana A. Leal, M.D.

The data being presented in this oral presentation comprise updated clinical data from the ongoing Phase 2 trial of sitravatinib in combination with OPDIVO® (nivolumab) for the treatment of non-small cell lung cancer (NSCLC) patients who have progressed on prior immune checkpoint inhibitor therapy. 

Investor Call and Webcast Information
In conjunction with the oral presentations, Mirati will host a live conference call and webcast, led by Dr. Charles Baum, on Monday, October 22, 2018, at 2:00 p.m. CEST/8:00 a.m. EDT/5:00 a.m. PDT. The live call can be accessed by dialing (866) 324-3683 (toll free) or (509) 844-0959 (international) and then using passcode 3890724. A telephone replay will be made available by dialing (855) 859-2056 (toll free) or (404) 537-3406 (international) using conference replay ID 3890724.  

The call will also be webcast live through the "Investors" section of the Mirati corporate website at A replay of the webcast will be available on the Mirati website shortly after the conclusion of the event.

About Sitravatinib

Sitravatinib is a spectrum-selective kinase inhibitor that potently inhibits receptor tyrosine kinases (RTKs), including TAM family receptors (TYRO3, Axl, Mer), split family receptors (VEGFR2, KIT) and RET. As an immuno-oncology agent, sitravatinib is being evaluated in combination with nivolumab (OPDIVO®), an anti-PD-1 checkpoint inhibitor, in patients who have experienced documented disease progression following treatment with a checkpoint inhibitor. Sitravatinib's potent inhibition of TAM and split family RTKs may overcome resistance to checkpoint inhibitor therapy through targeted reversal of an immunosuppressive tumor microenvironment, enhancing antigen-specific T cell response and expanding dendritic cell-dependent antigen presentation.

Sitravatinib is also being evaluated as a single agent in a Phase 1b expansion clinical trial enrolling patients whose tumors harbor specific mutations in the CBL kinase. When CBL is inactivated by mutation, multiple RTKs, including TAM, VEGFR2 and KIT, are dysregulated and may act as oncogenic tumor drivers in NSCLC and melanoma. Sitravatinib potently inhibits these RTKs and is being investigated as a treatment option for cancer patients with CBL mutations.

About Mirati Therapeutics

Mirati Therapeutics, Inc. is a clinical-stage oncology company developing product candidates to address the genetic, epigenetic and immunological promoters of cancer. Our precision oncology clinical programs utilize next-generation genomic testing to identify and select cancer patients who we believe would be most likely to benefit from targeted drug treatment. In immuno-oncology, we are advancing clinical programs where our product candidates have the potential to improve the immune environment of tumor cells and may enhance and expand the efficacy of existing cancer immunotherapy medicines when given in combination. Our pre-clinical programs include potentially first-in-class and best-in-class product candidates specifically designed to address mutations and tumors where few treatment options exist. We approach each of our discovery and development programs with a singular focus: to translate our deep understanding of the molecular drivers of cancer into better therapies and better outcomes for patients. For more information, visit

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release regarding the business of Mirati Therapeutics, Inc. ("Mirati") that are not historical facts may be considered "forward-looking statements," including without limitation statements regarding Mirati's development plans and timelines, potential regulatory actions, expected use of cash resources, the timing and results of clinical trials, and the potential benefits of and markets for Mirati's product candidates. Forward-looking statements are typically, but not always, identified by the use of words such as "may," "will," "would," "believe," "intend," "plan," "anticipate," "estimate," "expect," and other similar terminology indicating future results. Forward-looking statements are based on current expectations of management and on what management believes to be reasonable assumptions based on information currently available to them, and are subject to risks and uncertainties. Such risks and uncertainties may cause actual results to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include without limitation potential delays in development timelines, negative clinical trial results, reliance on third parties for development efforts, changes in the competitive landscape, changes in the standard of care, as well as other risks detailed in Mirati's recent filings on Forms 10-K and 10-Q with the U.S. Securities and Exchange Commission. Except as required by law, Mirati undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.

Logo (PRNewsfoto/Mirati Therapeutics, Inc.)


Cision View original content to download multimedia:

SOURCE Mirati Therapeutics, Inc.

Media and Investor Relations Contact: Temre Johnson, Mirati Therapeutics Inc., Director, Investor Relations & Corporate Communications, (858) 332-3562,

Categories: Press Releases
View all news